Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (Dr. M. Slaoui) and a connected person, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to executive compensation disclosures.
Material Changes
On February 17, 2009, a connected person of Dr. M. Slaoui received equity awards totaling 10,050 American Depositary Shares (ADSs). The breakdown of awards is as follows:
- Share Option Plan: 5,940 ADSs with an exercise price of US$33.42 per ADS.
- Share Value Plan: 1,490 ADSs.
- Performance Share Plan: 2,620 ADSs.
All awards have a vesting date of February 17, 2012. The Performance Share Plan award is contingent upon the Remuneration Committee determining that performance conditions are satisfied.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific equity grant transaction disclosed under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of ADSs awarded to Dr. Slaoui's connected person (10,050).
- Confirm the exercise price of the Share Option Plan awards (US$33.42).
- Note the vesting date for all awards (February 17, 2012).
- Understand that the Performance Share Plan award is subject to performance conditions.